key: cord-0771174-7iwb1rx9
authors: Wang, Zai; Deng, Tingting; Zhang, Yulian; Niu, Wenquan; Nie, Qiangqiang; Yang, Shengnan; Liu, Peipei; Pei, Pengfei; Chen, Long; Li, Haibo; Cao, Bin
title: ACE2 can act as the secondary receptor in the FcγR-dependent ADE of SARS-CoV-2 infection
date: 2021-12-31
journal: iScience
DOI: 10.1016/j.isci.2021.103720
sha: c5882b4a40c9a5e8e5c71dc50bd34b73b145787e
doc_id: 771174
cord_uid: 7iwb1rx9

It is unknown whether antibody-mediated enhancement (ADE) contributes to the pathogenesis of COVID-19, and the conditions for ADE needs to be elucidated. We demonstrated that without inducing an ACE2-independent ADE on Raji cells, the neutralizing antibody CB6, a mouse anti-S1 serum and convalescent plasma induced ADE on cells expressing FcγRIIA/CD32A and low levels of endogenous ACE2. ADE occurred at sub-neutralizing antibody concentrations, indicating that unneutralized S protein was required for ADE. The enhanced infectivity of 614G variant was higher than that of 614D wildtype in the presence of antibodies, further suggesting that ADE may be influenced by virus strains with different ACE2 binding affinity. Finally, knockdown of ACE2 or treatment with a fusion-inhibition peptide EK1C4 significantly reduced ADE. In conclusion, we identified an ADE mechanism mediated by neutralizing antibodies against SARS-CoV-2. ACE2 may act as a secondary receptor required for the antibody- and FcγR-mediated enhanced entry of SARS-CoV-2.

It is unknown whether antibody-mediated enhancement (ADE) contributes to the pathogenesis of COVID-19, and the conditions for ADE needs to be elucidated. We demonstrated that without inducing an ACE2-independent ADE on Raji cells, the neutralizing antibody CB6, a mouse anti-S1 serum and convalescent plasma induced ADE on cells expressing FcγRIIA/CD32A and low levels of endogenous ACE2. ADE occurred at sub-neutralizing antibody concentrations, indicating that unneutralized S protein was required for ADE. The enhanced infectivity of 614G variant was higher than that of 614D wildtype in the presence of antibodies, further suggesting that ADE may be influenced by virus strains with different ACE2 binding affinity. Finally, knockdown of ACE2 or treatment with a fusioninhibition peptide EK1C4 significantly reduced ADE. In conclusion, we identified an ADE mechanism mediated by neutralizing antibodies against SARS-CoV-2. ACE2 may act as a secondary receptor required for the antibody-and FcγR-mediated enhanced entry of SARS-CoV-2.

J o u r n a l P r e -p r o o f INTRODUCTION Antibody-dependent enhancement (ADE) is considered to be a potential challenge in the development of COVID-19 vaccine and the application of therapeutic antibodies (Lee et al., 2020; Ricke, 2021) . Although introducing mutations in the Fc region of a therapeutic antibody may fully abolish its interaction with Fc receptors and its potential ADE effect (Chu et al., 2020; Shi et al., 2020) , an intervention method is not available for use with the antibodies persistently present in the convalescent patients as well as in vaccinated individuals. Therefore, it is critically important to study the ADE potential of SARS-CoV-2 antibodies generated in human bodies, and to elucidate the underlying mechanism of ADE in SARS-CoV-2 infection.

Evidence acquired in vitro shows that antibodies targeting specific epitopes may have the ADE potential in SARS-CoV-2 infection (Chu et al., 2020; Li et al., 2021; Liu et al., 2021; Wu et al., 2020; Zhou et al., 2021) , although the pathogenic consequences of ADE in humans is controversial (Chan et al., 2020; Garcia-Nicolas et al., 2021) . However, some evidences showed that afucosylated antiviral IgG1 may be the trigger of the excessive inflammation observed in patients with severe COVID-19 (Larsen et al., 2021) and increased lung inflammation occurred in rare SARS-CoV-2 antibody-infused macaques (Li et al., 2021) . Although the in vivo ADE may be milder than observed in the in vitro systems, the reason for this inconsistency is not clear, and the in vivo conditions for ADE to occur is critically important to understand.

The effect of ADE was first detected in dengue virus infections (Dejnirattisai et al., 2010) and subsequently in patients infected with HIV (Robinson et al., 1988) , influenza virus (Ochiai et al., 1992) , FIPV (Olsen et al., 1992) and Ebola virus (Kuzmina et al., 2018) . Most of these viruses can infect immune cells, particularly macrophages. However, it is unknown whether a virus receptor-J o u r n a l P r e -p r o o f mediated basal level of infection is required for ADE. The possibility of simultaneous involvement of the virus receptor and Fcγ receptor (FcγR) in ADE is called the 'dual-receptor mechanism' (Arvin et al., 2020) . However, this hypothesis has long been debated, for example, the role of CD4 in the ADE of HIV (Homsy et al., 1989; Perno et al., 1990; Takeda et al., 1990) . The inability of ACE2 antibodies to inhibit SARS-CoV ADE (Kam et al., 2007) and the lack of or low levels of ACE2 expression on the target cells for SARS-CoV or SARS-CoV-2 ADE assays also challenges this hypothesis (Chu et al., 2020; Jaume et al., 2011; Zhou et al., 2021) . In contrast, other reports support this hypothesis, such as antibodies could mediate ADE of SARS-CoV on a cell line HL-CZ coexpressing ACE2

and FcγRII (Wang et al., 2014) ; and some immune cell lines with FcγRII expression do not support ADE of SARS-CoV or SARS-CoV-2 infection (Chu et al., 2020; Jaume et al., 2011) .

Importantly, ADE always occurs at subneutralizing antibody concentrations (Jaume et al., 2011; Wan et al., 2020) , which means that when the ADE effect reaches the peak, it usually decreases with the further increase of antibody concentration. In case of dengue virus, at the concentration of subneutralizing antibody, the virus binds to FcγR through the antibody, and the viral E protein directly binds to LILR-B1, which results in the prevention of the expression of interferon-stimulated genes and lysosomal degradation of the virus. At high antibody concentration, the binding of the E protein to LILR-B1 was completely blocked by the antibody, resulting in FcγR internalized virus neutralization (Kulkarni, 2020) . It is also possible that antibody at high concentration will block the interaction of the virus with other cellular factors, such as the virus receptor. Based on this, we hypothesized that FcγR alone is insufficient for the ADE process, and the ADE process may also require other cellular factors.

Virus, antibodies and target cells with essential receptor expression are major J o u r n a l P r e -p r o o f components of the ADE system. However, their involvement in SARS-CoV-2 ADE is insufficiently understood. For the involvement of FcγRs on target cells, it has been demonstrated that while some antibodies targeting N-terminal domain (NTD) domain of S protein mediates ADE effect in an FcγR-independent manner (Li et al., 2021; Liu et al., 2021) , a group of neutralizing monoclonal antibody against receptor binding domain (RBD) can enhance the infectivity of SARS-CoV-2 pseudovirus, which is mediated by FcγRIIB or FcγRI in vitro (Chu et al., 2020; Li et al., 2021; Zhou et al., 2021) . However, it remains controversial whether antibody or convalescent plasma could mediate ADE on cells without ACE2 expression, which is the same virus receptor as used by SARS-CoV (Zhou et al., 2020) . A preprint report showed that part of plasma from convalescent patient showed ADE effect on Raji cells and even peripheral blood mononuclear cells (PBMCs), with a much higher percentage in patients with severe vs. mild infections (Wu et al., 2020) , while convalescent plasma could not mediate ADE on Raji cells in another study (Zhou et al., 2021) . On the aspect of antibodies, available evidence does not clarify whether the ADE effect correlated with concentrations of neutralizing antibodies (Zhou et al., 2021) . On the aspect of virus, no study, to our knowledge, approached yet whether the epidemic strains with different binding affinities to ACE2 affect the level of ADE.

To answer these critically important questions and to further illuminate the role of the ACE2-mediated viral entry pathway in the SARS-CoV-2 ADE process, we used the monoclonal antibody CB6, a mouse anti-S1 serum and convalescent plasma to study the effect of ADE on immune cells or on exogenic FcγR-expressing cells.

We show here that these antibodies can elicit ADE on cells with FcγRIIA/CD32A expression and low level of endogenous ACE2. We conclude that FcγR, ACE2 and membrane fusion are essential for this ADE process, which is different from known mechanisms of ADE.

J o u r n a l P r e -p r o o f

To investigate the ADE ability of SARS-CoV-2, we prepared HIV/SARS-CoV-2 pseudovirus bearing the S protein with 614D or 614G mutation as previously reported ( Figure S1A ). The infectivity of 614G virus on difference cells was correlated with cellular ACE2 expression ( Figure 1A and B).

We also prepared neutralizing monoclonal antibodies CB6 (Shi et al., 2020) and XG005 ( Figure 1C ), the non-neutralizing anti-RBD N1G12 and anti-S2 monoclonal antibodies in human IgG1 isotype ( Figure S2A -D) and mouse antisera by immunizing Balb/c mice with S1 protein.

We first evaluated the ADE ability of XG005 on Raji, THP-1 and Daudi cells. As previously reported, XG005 mediated enhanced infectivity of 614G pseudovirus on Raji cells (Zhou et al., 2021) , as well as Daudi cells, but not THP-1 cells ( Figure 1D ). Next, we tested CB6 and convalescent plasma from three patients on these cell lines, as well as PBMCs. All these immune cells expressed FcγRs on their surfaces ( Figure S3A and B). THP-1 has been used in ADE assays for SARS-CoV, MERS-CoV and Ebola virus. However, CB6 antibody did not mediate ADE of SARS-CoV-2 614G on THP-1 cells ( Figure 1E ). In contrast, Daudi cells supported a weak ADE of the 614G but not 614D pseudovirus, with the relative luminescence unit (RLU) increased from 51.3 ± 5.1 to 93 ± 24.3 ( Figure 1E ). Since the SARS-CoV-2 pseudovirus bearing 614G mutation achieved 2-fold higher infectivity (Korber et al., 2020) than the 614D pseudovirus on Cos7 cells overexpressing human ACE2 (Cos7-hACE2) ( Figure S1A ), we suspected that the infectivity of 614D was undetectable even in the presence of ADE on Daudi cells, because the immune cells were generally not susceptible to SARS-CoV-2 infection ( Figure 1A ). Based on its higher infectivity and detection sensitivity, 614G was used in most of our subsequent ADE assays. Consistent with these findings, Daudi cells also supported a weak ADE mediated by mouse anti-S1 serum on 614G variant, with the RLU increased J o u r n a l P r e -p r o o f from 51.3 ± 5.1 to 111.7 ± 21.2 ( Figure 1F ). Although the convalescent plasma did not generate detectable ADE on these cells ( Figure 1F ), we reasoned that it was partially caused by the insufficient sensitivity of ADE assay based on the use of these cells. As controls, the ADE of MERS-CoV and MARV pseudoviruses on THP-1 cells were tested parallelly, whose ADE were obviously detected in the presence of their respective specific neutralizing antibodies ( Figure S4A -D) .

CD32A serves as the functional FcγR that mediates ADE.

Since the detection window was quite narrow using Daudi cells to evaluate SARS-CoV-2 ADE, we sought to establish a more sensitive ADE assay system. Based on the observation that THP-1 cells showed a certain degree of susceptibility to MERS-CoV and MARV, and could support ADE of both viruses, we suspected that THP-1 cells could not support ADE of SARS-CoV-2 because of complete lack of susceptibility, which was affected by ACE2 expression ( Figure 1A and B). We chose to overexpress FcγRs in Huh7 cells, which showed a degree of ACE2 expression and were partially susceptible to SARS-CoV-2 614G pseudovirus ( Figure 1A ( Figure S5A and B). Since FCER1G could facilitate the surface expression of CD16A (Hibbs et al., 1989) , we also co-expressed CD16A and FCER1G, which generated an enhanced surface expression of CD16A ( Figure S5E ). In the ADE assay mediated by was observed at lower concentrations tested (Figure 2A ; Figure S5F ). These results indicate that CD32A may function in the IgG1-mediated infection enhancement of SARS-CoV-2. We therefore employed Huh7-CD32A in the subsequent ADE assays.

To further investigate the requirement of cell susceptibility for ADE induction, we also overexpressed FcγRs in HeLa cells (Figure S5C and D) . In the ADE assay of 614G variant mediated by CB6 IgG1, none of the FcγR-overexpressing HeLa cells supported ADE ( Figure 2B ). When CD32A was overexpressed in HeLa-hACE2 cells to generate HeLa-hACE2-CD32A ( Figure S5G ), only neutralizing ability was detected for CB6 at high concentrations and ADE was undetectable at lower concentrations ( Figure 2C ). These results indicate that an appropriate level of susceptibility, e.g. not completely unsusceptible or highly susceptible, may be suitable for ADE induction.

We found that the non-neutralizing antibodies N1G12 and anti-S2 ( Figure S2A -C) showed no ADE effect for SARS-CoV-2 614G pseudovirus ( Figure 2D ). When we evaluated the ADE potential of different isotypes of CB6 antibodies, we found that only CB6 IgG1 mediated the ADE effect on Huh7-CD32A cells. The IgM and IgA isotypes of CB6 possessed neutralizing ability similar to that of CB6 IgG1 ( Figure S2A and B), but did not show ADE effect on Huh7-CD32A cells ( Figure 2D ).

Since IgM and IgA bind to Fc α receptors (FcαRs) instead of FcγRs, this result imply that the interaction of Fc domain with its specific receptor was required for the ADE effect.

Recently, numerous SARS-CoV-2 variants of concern show different infectivity and different susceptibility to neutralizing mAbs. We therefore prepared pseudotyped J o u r n a l P r e -p r o o f viruses bearing S with N501Y or E484K-N501Y mutations based on the 614G variant, as well as all mutations in B.1.351 strain. CB6 showed similar neutralizing ability to the 614D and 614G variants, but impaired neutralizing ability to the N501Y variant, and further impaired neutralization of the E484K-N501Y variant;

while no neutralization was observed on B.1.351 strain ( Figure 2E ). In ADE assays, CB6 mediated enhanced infectivity of the variants it could neutralize, but not that of B.1.351 ( Figure 2F ). Interestingly, the maximum ADE induction concentration of CB6 for different variants showed a trend of correlating with its IC50 (r=0.8693, p=0.0677) ( Figure S5H ); ADE occurred at the subneutralizing concentrations of CB6 for all the four variants.

We raised mouse antisera immunized with SARS-CoV-2 S1 protein (614D) to simulate vaccinated antisera. Antisera obtained from three mice showed strong neutralization of SARS-CoV-2, with similar IC50 values for 614D and 614G ( Figure   3A and B). The three antisera showed an ADE effect on Huh7-CD32A cells for both 614D and 614G viruses ( Figure 3C and D). It was noted that IC50 of serum from mouse 1 was lower than that of mouse 2 and 3 ( Figure 3A and B), and the maximum ADE induction concentration of mouse 1 serum was also lower than that of mouse 2 and 3 ( Figure 3C and D), suggesting that the ADE induction concentration of the antibody may be related to its neutralization activity.

To further investigate the relationship of the neutralizing ability of the antibody and the maximum induction concentration of ADE, we collected plasma samples from 150 convalescent patients six months after discharge. The disease severity scores of all patients ranged from 3 (hospitalized, not requiring supplemental oxygen) to 6 (hospitalized, requiring ECMO, invasive mechanical ventilation, or both) according to the seven-category ordinal scale (Cao et al., 2020) . We performed neutralization and ADE assays using these plasma samples. We tested the neutralization ability against 614G variant as well as the ADE J o u r n a l P r e -p r o o f potential of plasma from 93 convalescent patients, including all patients with severity scales of 3 (14 patients), 5 (8 patients) and 6 (1 patient), and equal numbers (35 patients) of male and female patients with a severity scale of 4.

All 93 plasma samples showed neutralization ability against 614G variant with IC50 values ranging from 0.06% to 0.76% ( Figure 4A ).

Among 93 plasma samples tested, 90 plasma exhibited canonical bell-shaped ADE curves, suggesting that most had the potential to cause ADE. Seven representative ADE curves generated by plasma taken from patients with different disease severities are shown ( Figure 4B ). To determine the maximum ADE induction concentration for each convalescent plasma, a non-linear regression curve was fitted according to the relative infectivity values, and the plasma concentration corresponding to the maximum infection value was calculated ( Figure S6A ). Based on the 90 plasma samples with an ADE potential, a medium correlation was found between the IC50 of 614G and the maximum induction concentration of ADE (Pearson r = 0.7207, p < 0.0001). The maximum induction concentration of ADE was generally lower than the IC50 ( Figure 4C ). Convalescent plasma from the severe groups mediate a stronger ADE effect than those from the mild group.

We analyzed the relationship of the neutralization and ADE characteristics of the convalescent plasma with clinical features. A weak negative correlation between IC50 of 614D wildtype virus and age was observed (Pearson r = -0.2639, p = 0.0012) ( Figure S6B ), with the decrease in IC50 paralleling the increasing age.

In particular, the prediction of a high IC50 was significant among patients aged ≥ 60 years ( Figure S6C ). In contrast, from IC50, the peak level of ADE of 614G virus showed no correlation with age ( Figure S6D ).

Among 93 convalescent plasma samples, although the IC50 of the 614G virus did not J o u r n a l P r e -p r o o f differ among severity groups, there was a trend showing that the IC50 was lower in the scale 5+6 group compared with those of the scale 3 (p = 0.12) and scale 4 (p = 0.06) groups ( Figure 5A ). The maximum infectivities in the presence of ADE differed significantly between scale 3 and scales 5 + 6 (p = 0.004), with convalescent plasma from scale 5 + 6 showing a stronger ADE effect compared with that of scale 3. There was no significant difference between scales 3 and 4, scale 4 and scale 5 + 6 ( Figure 5B ).

ACE2 can act as the secondary receptor in the FcγR-dependent ADE of SARS-CoV-2 Since binding to ACE2 causes a conformational change of the virus S protein, which leads to the protease cleavage and membrane fusion, we suspected that in the absence of the conformational changes caused by S-ACE2 binding, the virus may not be able to complete the subsequent proteolysis, membrane fusion and invasion, which are important for conventional infection as well as being indispensable for the ADE process.

To directly study the role of ACE2 in the ADE process, we first performed blocking experiments using the antibody against ACE2 or soluble ACE2 (sACE2). As a control, antibody against CD32 showed strong inhibition effect on 614G ADE ( Figure 6A ).

Anti-ACE2 antibody could also inhibited pseudovirus infection in the ADE assay ( Figure 6A ). However, the control IgG antibody also caused detectable inhibition ( Figure 6A ), suggesting nonspecific binding through the IgG-CD32A interaction.

Simultaneously, sACE2 significantly inhibited virus infection in the presence of antibodies ( Figure 6A ). This may be resulted from two possibilities: the sACE2 inhibited the binding of the antibodies to the virus; or the sACE2 blocked the binding of the virus to the membrane-localized ACE2 receptors.

To further elucidate the role of ACE2 in the ADE process, we established another J o u r n a l P r e -p r o o f CD32A-expressing cell line based on 293T cells, in order to utilize its high transfection efficiency. 293T cells had a similar ACE2 expression level as Huh7 cells and were partially susceptible to SARS-CoV-2 infection ( Figure 1A and B).

As expected, 293T-CD32A cells could support 614G ADE mediated by CB6 antibody.

We then knocked down the ACE2 expression by siRNA transfection (Figure 6B ), and measured the virus infectivity in the presence of CB6. Compared to the cells transfected with a non-targeting siRNA, the ADE level was significantly reduced in the siACE2 transfected cells ( Figure 6C ), proving that ACE2 was involved in the ADE process.

Further, to investigate whether the downstream event of S-ACE2 binding, such as membrane fusion, was involved in the ADE process, we applied the fusion inhibitory peptide EK1C4 to the ADE assay (Xia et al., 2020). We first verified that EK1C4 could inhibit the conventional 614G virus entry into Cos7-hACE2 cells ( Figure   6D ). Then we showed that compared with the control peptide, EK1C4 completely inhibited the 614G virus infectivity in the presence of CB6 antibody on both 293T-CD32A cells and Huh7-CD32A cells ( Figure 6E and F), indicating that the membrane fusion is also required for ADE.

Next, we asked whether the membrane fusion was involved in XG005-mediated enhanced infection, which could occur on Raji cells without ACE2 expression 

In this study, we utilized HIV-based lentiviral vectors to study the characteristics of the ADE effect of SARS-CoV-2. First, we found that immune cells were not susceptible to SARS-CoV-2 pseudovirus infection, and among the immune cells tested, including THP-1, Raji, Daudi and PBMC, only Daudi cells supported a weak ADE effect mediated by CB6 monoclonal antibody or mouse anti-S1 serum. THP-1 and Raji cells are often used in the ADE research (Jaume et al., 2011; Kuzmina et al., 2018; Wan et al., 2020) . We verified that THP-1 could support ADE for MARV and MERS-CoV; and Raji cells could support ADE mediated by another SARS-CoV-2 RBD-targeting monoclonal antibody XG005 (Zhou et al., 2021).

These results indicate that different antibodies may elicit ADE by different mechanisms, and FcγR may not be the only receptor required for ADE.

In our investigations of CB6-mediated ADE of SARS-CoV-2, we first identified CD32A as the functional FcγR molecule. We found that the exogenic CD32Aexpressing cells are more sensitive and reliable than immune cell lines for performing ADE assays of CB6 as well as mouse antisera and convalescent plasma.

For dengue virus, both CD32A and CD64A can mediated ADE, while CD32A functions more efficiently (Rodrigo et al., 2006) . In MERS-CoV and SARS-CoV infection, CD32A has been proposed as the functional Fc receptor that mediates ADE (Jaume et al., 2011; Wan et al., 2020) . While In filovirus infection, the binding affinity of Fc receptors to the IgG isoforms determines the extent of ADE. For antibodies in IgG1 isoform, blocking of CD64A significantly inhibits the ADE effect, which is consistent with the highest binding affinity of IgG1 to CD64A (Kuzmina et al., 2018) . However, it is unclear which FcγR contributes to the SARS-CoV-2 ADE effect. CD32 (Wu et al., 2020) , CD32B (Chu et al., 2020; Li et al., 2021) or CD64A (Li et al., 2021) has been shown to mediate ADE, which is different from our present findings. Based on the overexpression of individual FcγR molecules in Huh7 cells, we identified CD32A as the most efficient Fc J o u r n a l P r e -p r o o f receptor isoform that supported CB6 IgG1-mediated ADE effect.

The Fc-Fc receptor interaction plays a central role in the ADE process. In the previous reports, cells preincubated with antibodies against FcγRs could reduce the ADE effect. Removal of the Fc region (Wu et al., 2020) , or introducing L234A and L235A (LALA) mutations into the Fc region of the antibody (Chu et al., 2020) compromises the binding of the Fc fragment to the Fc receptor (Reusch and Tejada, 2015) Here we reveal the involvement of the ACE2-mediated virus entry pathway in the CB6 and antisera/plasma-mediated SARS-CoV-2 ADE process. This argument relies on the evidence as follows. First, the antibody-enhanced infectivity of the 614G variant was much higher than that of the 614D wildtype virus, which is consistent with their ACE2-binding affinities (Korber et al., 2020) . This led us to doubt whether SARS-CoV-2 ADE was based on the ACE2-mediated entry pathway.

Further, we found that the maximum ADE induction plasma concentration (plasma dilution) correlated with IC50 (plasma dilution) and ADE occurred only at subneutralizing concentrations, suggesting the possibility that the unneutralized S protein could bind to ACE2 to initiate the entry process. Together, our present findings support the conclusion that different antibodies may mediate ADE through different mechanisms. Under certain circumstance, ACE2 may act as the secondary receptor in the antibody and FcγR-mediated enhanced entry of SARS-CoV-2. In cells expressing FcγR but not ACE2, or in cells coexpressing ACE2 and FcγR, but in the presence of a high concentration of neutralizing antibodies, the virus can be bridged to FcγRs by the antibodies, but is unable to bind to ACE2. Due to the lack of ACE2-induced conformational changes of the S protein, the virus cannot complete the entry process required for the subsequent transport to the cytoplasm, and will be ultimately digested in the lysosomes. In cells coexpressing ACE2 and FcγR, sub-neutralizing antibody concentrations promote the attachment of the virus to the cells through Fc-FcγR interaction, as well as enable the unneutralized S protein to bind to ACE2 and initiate the entry procedure. Therefore, FcγR acts as an attachment factor to enhance the virus receptor-mediated invasion in the presence of sub-neutralizing antibodies (Figure 7 ).

We emphasize that although we found that most convalescent plasma exhibited ADE potential on Huh7-CD32A cells, they did not enhance virus infectivity of immune cell lines or PBMCs. Our results indicate that ADE might not be a common event in infected individuals. However, considering the diversity of antibodies and the variable status of immune cells in the human bodies, we cannot exclude the possibility that ADE may occur in special cases upon SARS-CoV-2 infection.

ACE2 is mainly expressed in type 2 alveolar epithelial cells, intestinal epithelial cells, bile duct cells, myocardial cells, and renal proximal tubular cells, but rarely expressed in immune cells (Qi et al., 2020) , implying that immune cells are not commonly susceptible to SARS-CoV-2 (Zhou et al., 2020).

However, the expression of ACE2 may be regulated by the pathophysiological state.

enhance the susceptibility to SARS-CoV-2 (Busnadiego et al., 2020) . Therefore, the expression of ACE2 may be up-regulated, because the inflammatory pathway is activated in COVID-19 patients . Therefore, the mechanisms of the expression regulation of ACE2 in immune cells under pathological conditions and its effect on potential ADE are critically important to explore in the future.

Due to the lack of live virus test, we cannot know whether the ADE process simulated by the pseudovirus is consistent with that of live virus. Especially, whether there is enhanced viral replication followed by the enhanced entry is unclear. In addition, the coexpression pattern of ACE2 and CD32A is not analyzed in the cells from SARS-CoV-2 infected individuals, which makes the possibility of ADE occurring in COVID-19 unclear. Data and code availability All data reported in this paper will be shared by the lead contact upon request. This paper does not report original code.

Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

EXPERIMENTAL MODELS AND SUBJECT DETAILS Antibodies, antisera/plasma and soluble ACE2 Humanized N1G12 and CB6 antibodies were generated by Shenzhen HeavyBio Technology.

The amino acid sequences of variable regions of heavy chain (CB6VH) and light chain (CB6VL) were obtained from GenBank (MT470197 and MT470196) (Shi et al., 2020 To obtain anti-SARS-CoV-2 mouse serum, 100 μg SARS-CoV-2 S1 protein (Shenzhen HeavyBio Technology) was mixed with Freund's adjuvant, immunized 6-8-week female Balb/c mice in the hindlimbs, boosted 3 weeks later, and the serum was collected 3 weeks later (Ruibiotech).

The recruitment criteria for COVID-19 patients and the sampling strategies have been reported previously (Cao et al., 2020) . All patients were hospitalized with COVID-19 of grade 3 or more on the seven-category ordinal scale (Cao et al., 2020) . The plasma from convalescent patients were collected 6 months after their discharge, with informed consent signed by every patient. The procedures were approved by the Ethics Committee of China-Japan Friendship Hospital (Beijing, China; KY-2020-78.01), and complied with all relevant ethical regulations regarding human research.

The extracellular domain of ACE2 (17-740 aa) with mutation in the enzyme activity site (H374N & H378N) and with a His tag (GGGSASHHHHHHHHHH) at C-terminus was expressed from 293T cells (originating from a female fetus) (Shenzhen HeavyBio Technology).

The spike gene of SARS-CoV-2 (Wuhan-Hu-1 strain and B.1.351 strain) was codonoptimized and cloned into BamHI/EcoRI in pcDNA3.1(+) with C-terminal 19-aa deletion 3 to generate pcDNA-SARS2-S . The spike genes with D614G, N501Y-614G, E484K-N501Y-D614G mutants, were generated by site-directed point mutation (TransGen Biotech). The MERS-CoV S gene was codon-optimized and cloned into pcDNA3.1(+) . The MARV glycoprotein expression vector was a gift from Dr. Linqi Zhang (Tsinghua University).

Human FcγR genes CD16A (NM_000569.8), CD32A (NM_001136219.3), CD32B (NM_001002273.3) and CD64A (NM_000566.4) were synthesized and cloned into XbaI/BamHI sites in pLenti-Cas9-Blast (Addgene) to substitute the Cas9 gene, and pLenti-CD16A-Blast, pLenti-CD32A-Blast, pLenti-CD32B-Blast and pLenti-CD64A-Blast were obtained. Human FCER1G gene was synthesized and cloned into EcoRI/BamHI sites in pCDH-EF1-MCS-IRES-puro to generate pcDH-FCER1G-puro. The vector pCDH-EF1-MCS-IRES-puro was constructed based on pcDH-EF1-MCS-T2A-puro (SBI System Biosciences) by synthesizing IRES sequence according to pIRES2-EGFP (Clontech) followed by puromycin coding sequence and cloning into NotI/SalI sites.

293T, THP-1 (male) and Raji (male) cells were from ATCC. Daudi (male) cells were from Nanjing Cobioer Gene Technology. Cos7-hACE2 cells (male) were from Beijing Vitalstar Biotechnology. Huh7 (male) and HeLa (female) cells were gifts from Dr. Linqi Zhang (Tsinghua University). PBMCs were separated from the whole blood donated by the authors (male) by a density gradient centrifugation method using histopaque 1077 (Sigma). Monocytes were purified using anti-CD14 beads (Miltenyi Biotec). 293T, Cos7-hACE2, Huh7 and its derivative cells were maintained in DMEM supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. Immune cells and cell lines were maintained in 1640 medium supplemented with 10% FBS and 1% penicillin/streptomycin. Cells were cultured at 37 °C with 5% CO2.

To generate FcγR-expressing cells, 1.5 μg pVSVG (Addgene), 2 μg pLP1, 2 μg pLP2 (YouBio) and 5 μg pLenti-CD16A/CD32A/CD32B/CD64A-Blast or pcDH-FCER1G-puro were cotransfected into 2.5 x 10 6 293T cells. The medium was changed 12 hours post transfection. The supernatants were collected 48 hours post transfection, and passed through a 0.45 μm filter (milipore). The supernatants were added to Huh7 or HeLa culture media with 8 μg/ml polybrene. 48 hours post infection, cells were selected by 10 μg/ml blasticidin or 5 μg/ml puromycin to generate Huh7-or HeLa-CD16A/CD32A/CD32B/CD64A cells or FCER1G expressing cells. 293T-CD32A cells were also generated according to the above method.

METHOD DETAILS siRNA transfection 293T cells were seeded at 2 x 10 5 per 3.5 cm dishes 24 hours before transfection. ELISA 0.1 μg His-tagged SARS-CoV-2 S1 protein expressed by HEK293S cells (Shenzhen HeavyBio Technology) in CBS buffer (1.6 g Na2CO3, 2.92 g NaHCO3/L) were coated on a 96-well microtiter plate (Solarbio) overnight at 4 °C. Wells were blocked with 5% non-fat milk in CBS buffer for 1 hour at 37°C, followed by incubation with serially diluted antibodies in 1% BSA/PBS for 1 hour at 37°C. Horseradish peroxidase (HRP)-conjugated goat anti-human IgG antibody (Solarbio) was added at 1:5000 dilution for 1 hour at 37°C. Colors were developed by adding TMB substrate for 10 minutes at 37°C and then stop buffer (Thermo Fisher Scientific) was added.

Plate was read at 450 nm on a Multiskan FC plate reader (Thermo Scientific, USA).

Real-time RT PCR 5 x 10 5 cells were seeded in 6 cm dish, lyzed by Trizol, and the total RNA was isolated. 

To detect ACE2 expression in 293T-CD32A cells, cells in 3.5 cm dishes were lysed in 100 μl SDS loading buffer. To detect S proteins in pseudotyped viruses, 5 ml 293T supernatant containing virus particles was passed through 0.22 μm filter, ultracentrifuged at 110,000 g x 90 min, resuspended in 50 μl 1 X SDS loading buffer, The lysates were subjected to 4-20% PAGE gel (Yeasen), transferred onto PVDF Immobilon®-Psq transfer membrane (Millipore). Blots were blocked with Odyssey® Blocking Buffer (TBS) (LI-COR Biosciences). First antibodies used were rabbit anti-ACE2 (Abcam), mouse anti-β-actin (Thermo Fisher Scientific), anti-S1 mouse serum and rabbit anti-p24 (Sino Biological Inc) as indicated. Secondary antibodies used were IRDye® 800CW Goat anti-Mouse IgG and IRDye® 680RD Goat anti-Rabbit IgG (LI-COR Biosciences). The blots were imaged on the Odyssey® CLx imaging system using 700 nm and 800 nm channels and analyzed using ImageStudio software (LI-COR Biosciences).

To detect CD16A, CD32A, CD32B and CD64A expression, 5 x 10 5 cells were incubated with anti-CD16 conjugated with BV421, anti-CD32 conjugated with FITC and anti-CD64 conjugated with APC (BD Biosciences) in 100 μl PBS containing 1% BSA. To detect CD16A expression in FCER1G co-expressed cell, anti-CD16 conjugated with Pacific blue (Beijing 4A Biotech) was used. After washing for three times with PBS, cells were resuspended in 500 μl PBS containing 1% BSA, passed through 40 μm cell strainer (BD Falcon) and then subjected to flow cytometry analysis. Non-targeting antibodies in IgG1 isotype conjugated with the same fluorophore were used as negative controls for each immune cell type. Huh7 or HeLa cells without FcγR overexpression stained with the same antibodies were used as the negative controls for their derivatives.

To test the binding ability of anti-S antibodies with S protein, pcDNA-SARS2-S was transfected into 293T cells. 48 hours later, the cells were trypsinized. 5 x 10 5 cells were resuspended in 100 μl binding buffer (Biolegend) and incubated with 2.5 or 10 ng/ml antibodies as indicated for 45 minutes on ice. After washing for three times, cells were resuspended in 100 μl binding buffer containing goat anti-human IgG conjugated with PE (Abcam) and incubated for 30 minutes on ice. After washing for three times, the cells were resuspended in 500 μl binding buffer, passed through 40 μm cell strainer (BD Falcon) and then subjected to flow cytometry analysis. Flow cytometry data were analyzed by FlowJo V10 (TreeStar).

To produce HIV-based pseudoviruses, 10 μg pNL Luc E-R-and 10 μg virus envelope protein expression vectors were co-transfected into 4.5 x 10 6 293T cells. The medium was replaced with fresh medium 12 hours later, and the supernatants of transfected cells were harvested 48 hours post transfection and passed through a 0.45 μm filter. The pseudotyped virus was normalized by p24 ELISA using a Vironostika HIV-1 Antigen MicroELISA Kit (Biomerieux bv, Boxtel). The supernatant containing 5 ng pseudotyped virus (p24) was used to infect cells in 96-well plates.

Neutralization, blockade and ADE assays Antibodies or antisera/plasma with a series of dilution was incubated with pseudovirus for 1 hour at 37℃ and then added to 7.5 x 10 3 Cos7-hACE2 cells for SARS-CoV-2 neutralization assay, to Huh7 cells for MERS-CoV and MARV neutralization assays; or added to 7.5 x 10 3 Huh7-derived cells, 293T-CD32A cells or 5 x 10 4 immune cells for ADE assays as indicated in the text.

For blockade assays by antibodies, 10 μg/ml antibodies were incubated with Huh7-CD32A cells at 4℃ for one hour. At the same time, 5 ng pseudotyped virus was incubated with 100 ng/ml CB6 antibody at 37℃ for one hour, and then the mixture was applied to the antibody-treated cells.

EK1C4 peptide (Xia et al., 2020) was kindly provided by Dr. Shibo Jiang and Dr. Lu Lu (Fudan University). Control peptide (YDHTKNYPFDVDQ) was derived from royal jelly and had no inhibition effect on SARS-CoV-2 entry as previously tested. For peptide blocking assay on Cos7-hACE2 cells, 5 ng pseudotyped virus was incubated with different concentrations of peptides at 37℃ for 30 minutes, and then the mixture was applied to the cells for 12 hours before the medium was changes. For peptide blocking assay for ADE, 5 ng pseudotyped virus was incubated with different concentrations of CB6 antibody as well as 3.2 μM peptides at 37℃ for 30 minutes, and then the mixture was applied to the cells for 12 hours before the medium was changes.

In all the above assays, the cells were lysed at 48 hours post infection, and luciferase activity was measured by the addition of equal volumn of luciferase substrate (Promega) and measured in a Spark ® multimode microplate reader (Tecan).

The titers of neutralizing antibodies were calculated as 50% inhibitory concentration (IC50) in neutralization assays.

QUANTIFICATION AND STATISTICAL ANALYSIS Student's t-test was used to compare the differences of continuous variables that met a normal distribution between two groups, and if the distribution deviates from a normal distribution, the Mann-Whitney U-test was used. In case of more than two-group comparisons, one-way analysis of variance followed by the Tukey's post hoc test was used. To calculate IC50, a non-linear regression curve was fitted based on the relative inhibition values. To derive the concentration of maximum induction of ADE, a non-linear regression curve was fitted based on the relative infectivity values. Repeated measurement of one-way ANOVA was used to compare the difference between the antibody-mediated enhanced infectivity and the infectivity at basal level. A linear regression model was used for correlation analysis. Cubic spline curve was plotted to illustrate the prediction for binarized IC50 of 614D variant with increasing age, and the magnitude of prediction is expressed as odds ratio (OR) and 95% confidence interval (CI). All statistical analyses were performed using the GraphPad Prism software version 8.01 (GraphPad Software, Inc.). P < 0.05 was considered statistically significant. ****p < 0.0001; ***p < 0.001; **p < 0.01; *p < 0.05; ns, not statistically significant. Data were derived from three independent experiments, and are presented as mean±SD. One-way ANOVA was used to compare the difference between HeLa cell and other cell groups. Repeated measurement of one-way ANOVA was used to compare the difference between the enhanced infectivity and the infectivity at basal level.*p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. Data were derived from three independent experiments, and are presented as mean±SD. Repeated measurement of one-way ANOVA was used to compare the difference between the enhanced infectivity and the infectivity at basal level. *p<0.05. 

A perspective on potential antibody-dependent enhancement of SARS-CoV-2

Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

Simulation of the Clinical and Pathological Manifestations of Coronavirus Disease 2019 (COVID-19) in a Golden Syrian Hamster Model: Implications for Disease Pathogenesis and Transmissibility

Comparative Replication and Immune Activation Profiles of SARS-CoV-2 and SARS-CoV in Human Lungs: An Ex Vivo Study With Implications for the Pathogenesis of COVID-19

Cross-reacting antibodies enhance dengue virus infection in humans

No Evidence for Human Monocyte-Derived Macrophage Infection and Antibody-Mediated Enhancement of SARS-CoV-2 Infection

Mechanisms for regulating expression of membrane isoforms of Fc gamma RIII (CD16)

The Fc and not CD4 receptor mediates antibody enhancement of HIV infection in human cells

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH-and cysteine protease-independent FcgammaR pathway

Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

Antibody-Dependent Enhancement of Viral Infections

Antibody-Dependent Enhancement of Ebola Virus Infection by Human Antibodies Isolated from Survivors

Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies

vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies

An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies

Infection enhancement of influenza A NWS virus in primary murine macrophages by anti-hemagglutinin monoclonal antibody

Monoclonal antibodies to the spike protein of feline infectious peritonitis virus mediate antibody-dependent enhancement of infection of feline macrophages

Infection of monocytes by human immunodeficiency virus type 1 blocked by inhibitors of CD4-gp120 binding, even in the presence of enhancing antibodies

Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses

Fc glycans of therapeutic antibodies as critical quality attributes

Two Different Antibody-Dependent Enhancement (ADE) Risks for SARS-CoV-2 Antibodies

Antibody-dependent enhancement of human immunodeficiency virus type 1 infection

Differential enhancement of dengue virus immune complex infectivity mediated by signaling-competent and signaling-incompetent human Fcgamma RIA (CD64) or FcgammaRIIA (CD32)

A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

Two receptors are required for antibody-dependent enhancement of human immunodeficiency virus type 1 infection: CD4 and Fc gamma R

Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry

Sunitinib reduces the infection of SARS-CoV, MERS-CoV and SARS-CoV-2 partially by inhibiting AP2M1

One-way ANOVA was used to compare the difference between groups. *p<0.05; ns, not significant

Figure 6. ACE2-mediated entry pathway is involved in SARS-CoV-2 ADE

Blockade assay performed on Huh7-CD32A cells. HIV/SARS-CoV-2 was incubated with

ng/ml CB6 IgG1 antibody as indicated, and applied to cells preincubated with anti-ACE2, anti-CD32 or IgG control as indicated. Or sACE2 was co

HIV/SARS-CoV-2 614G and 100 ng/ml CB6 IgG1 antibody, and then applied to the cells

Knockdown of ACE2 expression in 293T-CD32A cells by siRNA transfection. ACE2 protein level was detected by Western blot. ACE2 mRNA level was detected by realtime RT PCR

Effect of ACE2 knockdown on SARS-CoV-2 614G ADE. 293T-CD32A cells transfected with or without siACE2 were infected with HIV/SARS-CoV-2 in the presence of different concentrations of CB6

Inhibition efficiency of fusion inhibitory peptide EK1C4 on HIV/SARS-CoV-2 614G on Cos7-hACE2 cells

Effect of EK1C4 on CB6-mediated SARS-CoV-2 614G ADE on 293T-CD32A (E) and Huh7-CD32A (F) cells

Data were derived from three independent experiments, and are presented as mean±SD. One-way ANOVA was used to compare the difference between CB6 group and other groups

Figure 7. ADE of ACE2-mediated entry pathway in SARS-CoV-2 infection

FcγR acts as an attachment factor to enhance the virus receptor-mediated invasion in the presence of sub-neutralizing antibodies